Vita Life Sciences (ASX:VLS) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

VLS Aktienübersicht

VLS fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	6/6
Financial Health	6/6
Dividends	4/6

Belohnungen

3.9% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Die Erträge stiegen im vergangenen Jahr um 28.2%

Risikoanalyse

Unbeständige Dividendenentwicklung

Signifikante Insiderverkäufe in den letzten 3 Monaten

Hat keine nennenswerte Marktkapitalisierung (A$131M)

Vita Life Sciences Limited Wettbewerber

Probiotec

ASX:PBP

AU$246.4m

Vitura Health

ASX:VIT

AU$46.6m

ECS Botanics Holdings

ASX:ECS

AU$23.2m

Cryosite

ASX:CTE

AU$52.2m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Vita Life Sciences
Historical stock prices
Current Share Price	AU$2.25
52 Week High	AU$2.50
52 Week Low	AU$1.42
Beta	0.45
1 Month Change	-0.88%
3 Month Change	2.74%
1 Year Change	45.16%
3 Year Change	87.50%
5 Year Change	167.86%
Change since IPO	1,223.53%

Aktuelle Nachrichten und Updates

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14

Recent updates

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 28

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Dec 20

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Aug 24

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

May 14

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Mar 18

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Feb 17

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Jan 20

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Dec 22

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Nov 19

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Jul 14

Aktionärsrenditen

	VLS	AU Pharmaceuticals	AU Markt
7D	-4.3%	5.6%	-0.3%
1Y	45.2%	64.1%	8.5%

Rendite im Vergleich zur Industrie: VLS unter dem Niveau der Branche Australian Pharmaceuticals, die im vergangenen Jahr eine Rendite von 56.2% erzielte.

Rendite vs. Markt: VLS übertraf den Markt Australian, der im vergangenen Jahr eine Rendite von 8.8 erzielte.

Preisvolatilität

Is VLS's price volatile compared to industry and market?
VLS volatility
VLS Average Weekly Movement	6.4%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	8.8%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	3.3%

Stabiler Aktienkurs: VLS hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: VLSDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1947	n/a	Andrew O'Keefe	vitalifesciences.com

Vita Life Sciences Limited, ein Gesundheitsunternehmen, beschäftigt sich mit der Formulierung, Verpackung, dem Vertrieb und Verkauf von Vitaminen und Nahrungsergänzungsmitteln in Australien, Singapur, Malaysia, Thailand, Vietnam, Indonesien und China. Das Unternehmen bietet auch verschiedene Mineralien, Kräuter und Supernahrungsmittel an. Darüber hinaus bietet es Produkte für therapeutische Bereiche wie Nervensystem, Ernährung, Gesundheit der Harnwege, Gewichtsmanagement, Immunität, Haut, Haare und Nägel, Leber und Verdauung, Fruchtbarkeit, Schwangerschaft und Wochenbett, Blutzuckermanagement, Herz-Kreislauf-Gesundheit, Schmerzen und Entzündungen, Gesundheit von Männern, Frauen und Kindern, Antioxidantien, Knochen, Gelenke und Muskeln sowie Augengesundheit.

Vita Life Sciences Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Vita Life Sciences im Vergleich zum Marktanteil des Unternehmens?
VLS grundlegende Statistiken
Marktanteil	AU$125.42m
Gewinn(TTM)	AU$9.08m
Umsatz(TTM)	AU$74.16m

13.8x

Kurs-Gewinn-Verhältnis

1.7x

Kurs-Umsatz-Verhältnis

Ist VLS zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
VLS Gewinn- und Verlustrechnung (TTM)
Einnahmen	AU$74.16m
Kosten der Einnahmen	AU$31.05m
Bruttogewinn	AU$43.12m
Sonstige Ausgaben	AU$34.04m
Umsatz	AU$9.08m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.16
Bruttomarge	58.14%
Nettogewinnspanne	12.24%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich VLS auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

4.0%

Aktuelle Dividendenrendite

53%

Ausschüttungsquote

VLS Aktienübersicht

Belohnungen

Risikoanalyse

Vita Life Sciences Limited Wettbewerber

ASX:PBP

AU$246.4m

ASX:VIT

AU$46.6m

ASX:ECS

AU$23.2m

ASX:CTE

AU$52.2m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Upcoming dividend of AU$0.06 per share

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Recent updates

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Upcoming dividend of AU$0.06 per share

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

New minor risk - Insider selling

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Upcoming dividend of AU$0.03 per share at 3.7% yield

First half 2023 earnings released: EPS: AU$0.074 (vs AU$0.069 in 1H 2022)

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

Investor sentiment improves as stock rises 15%

Upcoming dividend of AU$0.033 per share at 3.9% yield

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Non-Executive Chairman exercised options to buy AU$433k worth of stock.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of AU$0.028 per share

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Independent Non-Executive Director Jonathan Tooth has left the company

Investor sentiment improved over the past week

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Investor sentiment improved over the past week

Upcoming Dividend of AU$0.028 Per Share

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

New 90-day high: AU$1.00

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Upcoming Dividend of AU$0.015 Per Share

New 90-day high - AU$0.95

First half earnings released

New 90-day high - AU$0.70

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Aktionärsrenditen

Preisvolatilität

Erträge & Einnahmen